VEGFA and age-related macular degeneration: Results of clinical trials such as CATT (Comparison of AMD Treatments Trials), MANTA (Multicentre Anti-VEGF Trial in Austria), IVAN (The Inhibition of VEGF in Age-related choroidal Neovascularization), LUCAS (Lucentis Compared to Avastin Study), and GEFAL (Groupe d'Etude Français Avastin versus Lucentis ) showed the noninferiority of bevacizumab in comparison to ranibizumab with the same safety profile[2,3,4,5,6].